Aly El Banayosy, MD
Cardiovascular Disease · Oklahoma City, OKNPI 1710147129
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 44.2% of the total. Reporting peaked in 2019 at $21,581 and has fallen 86.9% since, to $2,834 in 2025. Among cardiovascular disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $333.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$24K
- Abbott$20K
- Abiomed$8K
- Michigan Critical Care Consultants, Inc.$2K
- Getinge USA Sales, LLC$310
- Medtronic$51
- plus $117 from 5 others
What the payments were for
- Consulting fees$21,29239%
- Speaking & faculty fees$16,12530%
- Travel & lodging$8,37615%
- Food & beverage$7,72714%
- Education$5621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 21 | $23,878 |
| Abbott | 79 | $19,613 |
| Abiomed | 48 | $8,198 |
| Michigan Critical Care Consultants, Inc. | 2 | $1,915 |
| Getinge USA Sales, LLC | 4 | $310 |
| Medtronic | 2 | $51 |
| Boehringer Ingelheim | 2 | $43 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $19 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOVALUNG SYSTEM$7,612
- CentriMag$6,808
- Impella$5,025
- HeartMate 3 Left Ventricular Dev$4,638
- HeartMate 3 Left Ventricular Assist Device$2,625
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$2,357
- Soft Flow cannula$1,817
- Crescent cannula$1,817
- GALLANT$1,050
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$720
- CARDIOMEMS$126
- Absolute Pro vascular stent system$110
- CARDIOHELP$103
How this compares
$54,082 in reported general payments places this provider in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Oklahoma City
- Dwight ReynoldsOklahoma City$47K
- Udho ThadaniOklahoma City$41K
- Robert SullivanOklahoma City$36K
- Reji PappyOklahoma City$25K
- Sandeep ChopraOklahoma City$15K
- Jered CookOklahoma City$14K
- William CollazoOklahoma City$11K
- Vinodh JeevananthamOklahoma City$11K
- Niraj PrasadOklahoma City$10K
- Jeffrey AsburyOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.